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a b s t r a c t
Mutations in caveolin-3 (CAV3) can lead to different clinical phenotypes affecting skeletal or
cardiac muscles. Here, we describe a patient with Klinefelter syndrome, ulcerative colitis and
Sjögren syndrome, who developed transient hyperCKemia, myalgia and mild muscular
weakness. Using whole exome sequencing (WES), a missense mutation G169A was found in
the CAV3 gene. In addition, we identiﬁed a homozygous frameshift deletion in MS4A12 that
may contribute to inﬂammatory bowel disease, further demonstrating usefulness of WES in
dual molecular diagnoses.
# 2016 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.
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Caveolin-3 is a muscle-speciﬁc membrane protein. It is a
principal component of caveolae, the specialized lipid rafts of
the sarcolemmal membrane [1]. Mutations in the caveolin 3
gene (CAV3) lead to several different clinical phenotypes:* Corresponding author. Department of Neurology, Medical University
E-mail address: amkaminska@wum.edu.pl (A. Kaminska).
http://dx.doi.org/10.1016/j.pjnns.2016.06.008
0028-3843/# 2016 Polish Neurological Society. Published by Elsevier Sautosomal dominant limb-girdle muscular dystrophy type 1C
(LGMD1C) [2], rippling muscle disease [3], distal myopathy [4],
isolated hyperCKemia [5] and cardiomyopathy [6]; other
phenotypes e.g., long QT syndrome have been also reported
[7]. Patients may show an overlap of these symptoms and in
some cases the same mutation can lead to different
phenotypes [8–10,17]. Such abundance of phenotypes suggests of Warsaw, Banacha 1a, 02-097 Warsaw, Poland.
p. z o.o. All rights reserved.
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we present a case of a patient with a previously described
mutation in the CAV3 gene, accompanied by another genetic
condition (Klinefelter syndrome) and autoimmune diseases,
either of which could modify the phenotype of myopathy.
2. Case report
2.1. Patient's history
The patient was a 48-year-old male born of non-consanguine-
ous parents. His medical history included gonadal dysgenesia,
which led to diagnosis of Klinefelter syndrome made at the age
of 31 on the basis of testicle biopsy, increased LH and FSH
levels, and decreased testosterone, and conﬁrmed later by
karyotype analysis. The patient suffered also from ulcerative
colitis, with onset at the age of 46 years. Patient's deceased
mother had been diagnosed with extrapyramidal syndrome
(no detailed medical documentation was available); none of
the other family members had any neuromuscular symptoms.
First muscular symptoms started acutely at the age of 46
years in form of myalgia during an upper respiratory tract
infection. Other symptoms during the infection included
shortness of breath and macular rash on the cheeks and
upper torso. At that time, an increased creatine kinase (CK)
level of 1910 U/L was noted, as well as increased hs-troponin
and the NT-proBNP values. Inﬂammatory biomarkers were
also elevated: ESR 67 mm/h and C-reactive protein 30.4 ng/ml
(reference range <10). Antinuclear antibodies were present in
1:2560 titre, and anti-Ro and anti-La antibodies were detected.
Echocardiography did not reveal abnormalities of the heart,
the ejection fraction was 60%. Electromyography was general-
ly concluded as showing signs of generalized sensory-motor
polyneuropathy and myopathic changes in tibialis anterior
and ﬁst dorsal interosseous muscle (original recordings were
not available to us). On the basis of the clinical ﬁndings and
laboratory test results, the patient was diagnosed withFig. 1 – The patient's appearance (a). The elbows and knees shopolymyositis and received intravenous methylprednisolone
followed by oral prednisone 40 mg/d, with slow tapering to a
dose of 5 mg/over 16 months. After 2 weeks of treatment,
normalization of CK levels was observed. 3 months later, the
patient was hospitalized again. Creatine kinase level was
normal, rheumatoid factor was present (296 IU/ml, reference
range <34 IU/ml), and antinuclear (1:1280), anti-Ro (++ + ), and
anti_Ku (+) antibodies were positive. ESR was 24 mm.
Ophthalmologic Schirmer test was positive. A muscle biopsy
was ﬁxed in formaldehyde and only poor quality parafﬁn
sections were available, which revealed no signs of myositis or
vasculitis. Sparse atrophic muscle ﬁbers with multiple nuclei
and single hypertrophic ﬁbers were found (results not shown).
Electroneurography showed normal conduction velocities and
electromyography was normal. MR of the lumbosacral spine
demonstrated L4/L5 and L5/S1 disc bulging with mild
intevertebral foramen restriction. The patient was diagnosed
with Sjögren syndrome. Additionally, osteopenia, and vitamin
D deﬁciency were found.
Because of non-speciﬁc neuromuscular symptoms and
sporadic occurrence, WES analysis was performed to establish
possible genetic background. The results of the genetic
analysis (described below), pointed to a CAV3 mutation as
the cause of the myopathy. To evaluate the patient's
phenotype, he was admitted to our neurology department.
The patient's major complaints at that time were myalgias and
generalized weakness; he also reported problems with climb-
ing stairs and getting up from a sitting position.
2.2. Clinical examination
On admission into our department (16 months after ﬁrst
symptoms), the patient was alert and fully oriented in the
place and time. Scoliosis and varus deformity of the knees and
elbows were noticeable (Fig. 1). Mild atrophy of the calf
muscles was present. Signs of postthrombotic syndrome
were visible in the lower legs. On neurological examination,
the cranial nerves function was normal. Muscle strength in thew varus deformity. Note mild calf muscle atrophy (b and c).
Fig. 3 – DNA sequencing chromatogram of exon 2 of the
CAV-3 gene showing a heterozygous missense mutation c.
G169A in the proband.
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Lovett scale), and more prominent weakness of the left lower
limb was present, with degree difﬁcult to assess due to pain of
the left knee. There was also mild global sensory impairment
in the left lower limb. Deep tendon reﬂexes in the upper limb
were normal, while knee and ankle reﬂexes were markedly
decreased. No pathological pyramidal signs were present.
2.3. Laboratory tests and diagnostic procedures
CK, blood count, urine, electrolytes, renal and hepatic
parameters, lipid proﬁle, thyroid hormones, vitamin B12,
and folic acid level were all in the normal range. Troponin I and
NT-proBNP levels were not elevated. Laboratory test abnor-
malities included slightly elevated ESR (15 mm/h), increased
follicle-stimulating and luteinizing hormone levels (respec-
tively: 24.81 mIU/ml, normal range 1.5–12.4 and 10.72 mIU/ml,
normal range 1.7–8.6) and increased level of gamma-globulins.
Electroneurography showed normal conduction parame-
ters in the peripheral nerves. Electromyographic parameters of
proximal and distal muscles of the limbs were normal.
Degenerative changes of the left hip joint were found in the
radiogram, while the radiogram of the left knee was normal.
Brain CT scan demonstrated no abnormalities. Ophthalmo-
logic examination with fundoscopy conﬁrmed dry eye syn-
drome and revealed a small retinal lesion of nondescript
character. Spirometry showed normal respiratory parameters.
MR of the thigh muscles showed no abnormalities (Fig. 2).
2.4. Molecular analyses
Patient's genomic DNA extracted from a peripheral blood was
analyzed using whole exome sequencing (WES) at Baylor
College of Medicine Human Genome Sequencing Center (BCM-
HGSC) through the Baylor Hopkins Center for Mendelian
Genomics as previously described [11–13].
From the initial set of all variants, we ﬁltered out
synonymous single nucleotide variants (SNVs) and variants
with minor allele frequency > 1% in 1000 Genomes [14], Exome
Variant Server [15], and in-house exome databases [16], which
left 705 potentially deleterious mutations (Supp Table 1). A
query for previously reported pathogenic variants revealed
nine variants annotated in Human Gene Mutation Database
(HGMD) as disease causing mutations (DMs) and three variantsFig. 2 – T1-weighted (a) and spectral fat-suppressed T2-weighte
signal from thigh muscles is normal in both sequences, withouannotated as likely DMs. We found that all but one of these
variants was observed in at least one of the above-mentioned
reference databases and thus they are less likely to contribute to
the patient's phenotype. The single HGMD-DM variant not
reported in external and internal exome datasets was a
missense mutation c.G169A; p.V57M in exon 2 of CAV3
(NM_001234; chr3:8787266 G > C [hg19]). The predictions from
MutationTaster, RadialSVM, Polyphen2, LRT, and Phylop con-
sistently classiﬁed this variant as conserved and deleterious.
Sanger sequencing conﬁrmed the mutation (Fig. 3) and showed
that it was absent in the patient's father and brother, and half-
sister. Unfortunately, the proband's mother is deceased and no
DNA sample is available for testing.
Besides the HGMD mutations, we investigated other
potentially pathogenic variants, including 68 novel, 113
putative compound heterozygous, and 54 homozygous variants
(Supp. Table 1). Among them, we identiﬁed an additional
variant that may contribute to the patient phenotype, i.e. the
homozygous frameshift deletion in MS4A12 (Membrane-span-
ning 4-domains subfamily A member 12) (NM_001164470;
chr11:60264977:CA > C). The allele frequency of this variant
in control databases vary between 0.22% and 0.36%.
2.5. Incidental conﬁrmation of Klinefelter syndrome
We performed the analysis of B-allele frequency data obtained
from WES to identify the regions with Absence of Heterozy-
gosity (AOH) which could potentially reveal the presence of
larger copy-number variants (CNVs) or suggest that parentsd (b) transverse MR image of the thighs of the patient. The
t signs of fatty degeneration or inflammatory changes.
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we noticed the excess of heterozygous SNPs on X chromo-
some in this male patient. Analysis of 100 WES cases (47 males
and 53 females) randomly selected from BH-CMG cohort
revealed that the fraction of heterozygous SNPs on
X chromosome vary from 0.13 to 0.22 (mean = 0.17) in males
and between 0.41 and 0.63 (mean = 0.56) in females. In our
patient, we found that the percentage of heterozygous SNPs
on X chromosome was 0.59, indicating the presence of two
X chromosomes, and further conﬁrming the previous cyto-
genetic diagnosis of 46,XXY (Klinefelter syndrome) in this
patient.
3. Discussion
CAV3 mutations can lead to different phenotypes: limb-girdle
muscular dystrophy type 1C (LGMD1C), rippling muscle
disease, distal myopathy, isolated hyperCKemia, and cardio-
myopathy. Moreover, the same mutation can cause different
phenotypes; variable as well as overlapping phenotypes have
been observed within families [8–10,17].
The described patient presents several symptoms found in
caveolinopathies, constellation of which cannot be classiﬁed
as one of the classic caveolinopathy phenotypes. Myalgia,
muscle weakness, and high CK levels are frequent symptoms
in patients with caveolinopathies. Despite the mild proximal
muscle weakness, however, the course of the disease in our
patient is different from LGMD1C, which is characterized by an
earlier onset (varying from 5 years to adulthood), mild-to-
moderate proximal muscle weakness, calf hypertrophy, and
progression of symptoms [18]. Our patient, in contrast to most
cases of LGMD1C, presented with slight atrophy of the calves,
which was more suggestive of distal myopathy [19]. Myalgia,
which was our patient's main complaint, is characteristic both
for LGMD1C and rippling muscle disease, however, we did not
ﬁnd clinical signs of rippling muscle disease in this case.
Interestingly, most patients with caveolinopathy, with the
exception of familial hypertrophic cardiomyopathy, have
persistently increased level of CK [9,20], whereas in our
patient hyper-CK-mia was transient.
Muscle biopsy of the presented patient showed very mild
myopathic changes (not shown), consistent with other
literature reports of muscle biopsy in caveolinopatihes [20].
In contrast, MR imaging demonstrated normal muscle tissue
(Fig. 3), while in both cases of rippling muscle disease and
LGMD caused by the CAV3 mutations, MR of the muscles
demonstrated fatty inﬁltration and atrophy of muscles of the
thigh [10,21,22].
The G169A mutation found in the described case had been
previously reported in families with asymptomatic hyperCK-
emia [23], autosomal dominant RMD [24] as well as in one
sporadic case of myotonia [25]. In contrast to those observa-
tions, our patient had clinical symptoms of myopathy, but
experienced only transient, infection-related, increased CK
levels; no signs of rippling muscles or myotonia were present
either clinically or on EMG studies. This is an interesting
phenomenon of the same mutation leading to different
phenotype that could be explained by the modifying effects
of other genes.The patient's Klinefelter syndrome could be a factor
contributing to neuromuscular symptoms, as muscle weak-
ness is often observed in Klinefelter syndrome [26]. Therefore,
the described case can constitute an example of genetic
‘‘double trouble’’ phenomenon. Recent genomic approaches to
disease, such as WES of a large cohort of subjects have
revealed that two or more pathogenic variants can be found in
as many as 5–7% of patients when compared with unrelated
control individuals [27]. These studies also facilitated dual
molecular diagnoses of ‘‘blended Mendelian phenotypes’’,
which should be taken into account in atypical presentation of
neuromuscular disorders, and have been described also in
caveolinopathy [28].
Moreover, the patient's muscular symptoms could be
attributed to the accompanying acquired diseases as well as
to the primary muscle disease. Increased troponin and NT-
proBNP levels accompanying transient hyper-CKmia could
suggest infective myocarditis despite the normal echocardi-
ography result. On the other hand, infection is often a
precipitating factor of rhabdomyolysis in patients with
hereditary myopathy. Our patient also has Sjögren syndrome,
in which diffuse myalgia and muscle weakness are commonly
found [29]. Of note, association of Klinefelter syndrome and
autoimmune disease, especially female-biased ones like
systemic lupus erythematosus or Sjögren syndrome, has been
described in several reports [30,31]. Asymmetrical left lower
limb weakness with accompanying pain could be also
explained by degenerative hip joint disease, however, asym-
metry has been found in caveolinopathies [8,19]. Therefore,
the patient's muscular symptoms could be a composite result
of several coexisting conditions. However, the fact that the
CAV3 mutation was not found in the patient's relatives
potentially implicates its pathogenic role in the described case.
Detection of Klinefelter syndrome by WES can be of
practical importance in the future, as this relatively common
chromosomal disorder is currently grossly underdiagnosed
[32].
Notably, WES revealed also a homozygous frameshift
deletion in MS4A12 that may contribute to another part of
patient's phenotype, inﬂammatory bowel disease. MS4A12 is a
cell surface protein found primarily in the apical membrane of
colonocytes and it was found that silencing of this gene in
colon cancer inhibits the proliferation, cell motility and
chemotactic invasion of cells [33]. Strict restriction of expres-
sion to colonocytes as well as involvement of MS4A12 in
modulation of EGFR signaling indicate an important role of
this protein in control of epithelial cell properties, such as
growth, healing, adhesion and cell migration. The involve-
ment of MS4A12 in inﬂammatory bowel disease has not been
studied, however, we hypothesize that homozygous loss of
function variant in MS4A12 gene could be at least a modifying
factor in this condition.
4. Conclusion
The CAV3 mutation phenotype spectrum can be extended to
transient hyperCKemia with mild muscular weakness and
myalgia, without overt dystrophic features in the muscle
biopsy and MR imaging. Co-existing Klinefelter syndrome as
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 5 0 ( 2 0 1 6 ) 4 6 8 – 4 7 3472well as accompanying autoimmune disorders can be the
phenotype-modifying factors in the described case. Hereditary
myopathy should be taken into consideration even in the
presence of other – genetic and acquired – diseases which
could account for muscular symptoms.
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